Template:Relative oral potencies of estrogens
From HandWiki
Revision as of 19:03, 20 June 2021 by imported>Jworkorg (import)
| Estrogen | Type | HF | VE | UCa | FSH | LH | HDL-C | SHBG | CBG | AGT | Liver |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Estradiol | Bioidentical | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Estrone | Bioidentical | ? | ? | ? | 0.3 | 0.3 | ? | ? | ? | ? | ? |
| Estriol | Bioidentical | 0.3 | 0.3 | 0.1 | 0.3 | 0.3 | 0.2 | ? | ? | ? | 0.67 |
| Estrone sulfate | Bioidentical | ? | 0.9 | 0.9 | 0.8–0.9 | 0.9 | 0.5 | 0.9 | 0.5–0.7 | 1.4–1.5 | 0.56–1.7 |
| Conjugated estrogens | Natural | 1.2 | 1.5 | 2.0 | 1.1–1.3 | 1.0 | 1.5 | 3.0–3.2 | 1.3–1.5 | 5.0 | 1.3–4.5 |
| Equilin sulfate | Natural | ? | ? | 1.0 | ? | ? | 6.0 | 7.5 | 6.0 | 7.5 | ? |
| Ethinylestradiol | Synthetic | 120 | 150 | 400 | 60–150 | 100 | 400 | 500–600 | 500–600 | 350 | 2.9–5.0 |
| Diethylstilbestrol | Synthetic | ? | ? | ? | 2.9–3.4 | ? | ? | 26–28 | 25–37 | 20 | 5.7–7.5 |
| Notes: Values are ratios, with estradiol as standard (i.e., 1.0). Abbreviations: HF = Clinical relief of hot flashes. VE = Increased proliferation of vaginal epithelium. UCa = Decrease in UCa. FSH = Suppression of FSH levels. LH = Suppression of LH levels. HDL-C, SHBG, CBG, and AGT = Increase in the serum levels of these liver proteins. Liver = Ratio of liver estrogenic effects to general/systemic estrogenic effects (specifically hot flashes relief and gonadotropin suppression). Type: Bioidentical = Identical to those found in humans. Natural = Naturally occurring but not identical to those found in humans (e.g., estrogens of other species). Synthetic = Man-made, does not occur naturally in animals or in the environment. Sources: [1][2][3][4][5][6][7][8][9][10] | |||||||||||
Template documentationSee also
References
- ↑ "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric 8 (Suppl 1): 3–63. 2005. doi:10.1080/13697130500148875. PMID 16112947. http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf.
- ↑ "Wirkspektrum unterschiedlicher Östrogene" (in de). Östrogene in Diagnostik und Therapie. Springer-Verlag. 1990. pp. 78–. ISBN 978-3-642-75101-1. https://books.google.com/books?id=IArLBgAAQBAJ&pg=PA78.
- ↑ (in de) Die Gynäkologie. Springer-Verlag. 2013. pp. 105–. ISBN 978-3-662-11496-4. https://books.google.com/books?id=1pwiBgAAQBAJ&pg=PA105.
- ↑ Kuhl, H. (April 1997). "Metabolische Effekte der Östrogene und Gestagene" (in de). Der Gynäkologe 30 (4): 357–369. doi:10.1007/PL00003042. ISSN 0017-5994.
- ↑ "Therapeutic and Preventive Aspects of Estrogen and Progesterone Therapy". Comprehensive Management of Menopause. 1994. pp. 269–285. doi:10.1007/978-1-4612-4330-4_26. ISBN 978-1-4612-4330-4.
- ↑ "Potency and hepato-cellular effects of oestrogens after oral, percutaneous, and subcutaneous administration". Third International Congress on the Menopause, held in Ostend, Belgium, in June 1981, under the auspices of the International Menopause Society. 1982. pp. 103–125. doi:10.1007/978-94-011-7253-0_12. ISBN 978-94-011-7253-0.
- ↑ "Primary and Secondary Hypogonadism in Women". Endocrine Replacement Therapy in Clinical Practice. Springer Science & Business Media. 2003. pp. 471–505. doi:10.1007/978-1-59259-375-0_25. ISBN 978-1-59259-375-0. https://books.google.com/books?id=CA0HCAAAQBAJ&pg=PA471.
- ↑ "Comparison of pharmacodynamic properties of various estrogen formulations". Am. J. Obstet. Gynecol. 144 (5): 511–518. November 1982. doi:10.1016/0002-9378(82)90218-6. PMID 6291391.
- ↑ "Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects". Acta Obstet Gynecol Scand 61 (S107): 1–29. 1982. doi:10.3109/00016348209155333. PMID 6282033.
- ↑ "Biologic effects of equilin sulfate in postmenopausal women" (PDF). Fertil. Steril. 49 (2): 234–8. February 1988. doi:10.1016/S0015-0282(16)59708-8. PMID 3338581. https://www.fertstert.org/article/S0015-0282(16)59708-8/pdf.
